Teeple, A.; Muser, E. Cost Per Responder Analysis of Guselkumab Versus Certolizumab Pegol Using Efficacy Results from Pivotal Clinical Trials in Patients With Moderate to Severe Plaque Psoriasis. J of Skin 2018, 2, S80.